1. Search Result
Search Result
Isoforms Recommended: CYP51
Results for "

CYP-51

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

2

Natural
Products

2

Recombinant Proteins

2

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-168188

    Cytochrome P450 Infection
    CYP51-IN-21 (Compound A33) is a potent CYP51 inhibitor. CYP51-IN-21 shows excellent antifungal activities against pathogenic fungi and drug-resistant strains. CYP51-IN-21 inhibits the formation of fungal biofilm .
    CYP51-IN-21
  • HY-162370

    Cytochrome P450 Infection Cancer
    CYP51-IN-16 (compound C6) is a phenylpyrimidine CYP51 inhibitor, and shows antifungal activity in in vitro. CYP51-IN-16 inhibits tumor cell growth .
    CYP51-IN-16
  • HY-162784

    Fungal Cytochrome P450 Infection
    CYP51-IN-19 (compound C07) is a potent CYP51 inhibitor. CYP51-IN-19 stimulates reactive oxygen species (ROS) and exhibits potent fungicidal activity .
    CYP51-IN-19
  • HY-159585

    Cytochrome P450 Fungal Infection
    CYP51-IN-20 (compound 5b) is an inhibitor of CYP51 and has antifungal activity. CYP51-IN-20 has a significant inhibitory effect on Candida albicans ATCC 10231, downregulates ERG11 (Cyp51) gene expression, and significantly reduces the yeast-to-hyphae morphological transition. CYP51-IN-20 can synergize with Voriconazole (HY-76200) to occupy the entire CYP51 binding site and exert a synergistic inhibitory effect in the Glechoma moth model .
    CYP51-IN-20
  • HY-163571

    Fungal Cytochrome P450 Bacterial Infection
    CYP51-IN-17 (compound 7a) is a potent CYP51 inhibitor with an IC50 of 0.377 μg/mL. CYP51-IN-17 shows significant fungicidal activity against B. cinerea with an EC50 of 0.326 μg/mL .
    CYP51-IN-17
  • HY-163633

    Cytochrome P450 Fungal Bacterial Infection
    CYP51-IN-18 (compound 2l) is a potent CYP51 inhibitor with an IC50 of 0.219 μg/mL. CYP51-IN-18 shows significant fungicidal activity against B. cinerea with an EC50 of 0.369 μg/mL .
    CYP51-IN-18
  • HY-144643

    Fungal HDAC Cytochrome P450 Inflammation/Immunology
    CYP51/HDAC-IN-1 is a potent, orally active CYP51/HDAC dual inhibitor. CYP51/HDAC-IN-1 inhibits important virulence factors and down-regulated resistance-associated genes. CYP51/HDAC-IN-1 exhibits potent therapeutic effects for both tropical candidiasis and cryptococcal meningitis .
    CYP51/HDAC-IN-1
  • HY-157333

    Parasite Cytochrome P450 Infection Inflammation/Immunology
    CYP51-IN-15 (9B) is a BBB penetrated Naegleria fowleri-specific CYP51 inhibitor, with an EC50 of 1.5 μM .
    CYP51-IN-15
  • HY-149617

    Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target (CYP51/PD-L1) inhibitor, with IC50 values of 0.17 and 0.021 μM, respectively. CYP51/PD-L1-IN-4 exhibits excellent antifungal and antidrug-resistant fungal activity in vitro. CYP51/PD-L1-IN-4 can be used for fungal infections research .
    CYP51/PD-L1-IN-4
  • HY-156150

    Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-2 (compound L20) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-2 is a dual inhibitor of CYP51 (IC50: 0.263 μM) and PD-L1 (IC50: 0.017 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-2 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-2
  • HY-156151

    Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-3 (compound L21) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-3 is a dual inhibitor of CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-3 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-3
  • HY-156149

    Fungal Cytochrome P450 PD-1/PD-L1 Infection
    CYP51/PD-L1-IN-1 (compound L11) is a quinazoline compound with antifungal activity. CYP51/PD-L1-IN-1 is a dual inhibitor of CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), which can induce early apoptosis of fungal cells in the cell cycle. CYP51/PD-L1-IN-1 also significantly reduced intracellular IL-2, NLRP3, and NF-κBp65 protein levels, induced mitochondrial damage and ROS accumulation, and ultimately led to fungal lysis and death .
    CYP51/PD-L1-IN-1
  • HY-RS03486

    Small Interfering RNA (siRNA) Others

    CYP51A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP51A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CYP51A1 Human Pre-designed siRNA Set A
    CYP51A1 Human Pre-designed siRNA Set A
  • HY-155710

    Fungal Infection
    Antifungal agent 68 (compound 10) is an antifungal agent against Candida and Cryptococcus gattii. Antifungal agent 68 inhibits fungal ergosterol biosynthesis, possibly by targeting lanosterol 14α-demethylase (CYP51). There is an interaction between the imidazole ring of antifungal agent 68 and the heme group of CYP51 .
    Antifungal agent 68
  • HY-N7266

    Cytochrome P450 Parasite Infection Cancer
    Obtusifoliol is a specific CYP51 inhibitor, Obtusifoliol shows the affinity with Kd values of 1.2 μM and 1.4 μM for Trypanosoma brucei (TB) and human CYP51, respectively .
    Obtusifoliol
  • HY-B0852S

    Cytochrome P450 Fungal Infection
    Tebuconazole-d9 is the deuterium labeled Tebuconazole. Tebuconazole is an agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively.
    Tebuconazole-d9
  • HY-109040

    VT-1129

    Fungal Cytochrome P450 Infection
    Quilseconazole (VT-1129) is a potent, orally active fungal Cyp51 (lanosterol 14-α-demethylase) inhibitor, binds tightly to cryptococcal CYP51, but weakly inhibits humans CYP450 enzymes .
    Quilseconazole
  • HY-108938

    Cytochrome P450 Fungal Parasite Infection
    SDZ285428 is a CYP51 inhibitor. SDZ285428 inhibits Trypanosoma cruzi (TC) CYP51 with I/E2 <1 (5 min) and I/E2=9 (1 h). SDZ285428 inhibits Trypanosoma brucei (TB) CYP51 with I/E2 <1 (5 min) and I/E2=35 (1 h) .
    SDZ285428
  • HY-122410
    Dihydrolanosterol
    1 Publications Verification

    Cytochrome P450 Others
    Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor. .
    Dihydrolanosterol
  • HY-116568

    JAU-6476

    Fungal Cytochrome P450 Infection
    Prothioconazole is a triazolinthione fungicide. Prothioconazole is a CYP51 inhibitor .
    Prothioconazole
  • HY-151437

    Fungal Infection
    Antifungal agent 40 is an antifungal agent which extends into the narrow hydrophobic pocket II of C.alb. CYP51. Antifungal agent 40 has an inhibitory effect on lanosterol 14α-demethylase (CYP51). Antifungal agent 40 inhibits biofilm formation .
    Antifungal agent 40
  • HY-17643

    VT-1161

    Fungal Cytochrome P450 Infection
    Oteseconazole (VT-1161) is a potent and orally active anti-fungal agent. Oteseconazole potently binds to and inhibits Candida albicans cytochrome P45051 (CYP51) activity (Kd ≤39 nM), shows no obvious effect on human CYP51. Oteseconazole also can be used for the research of dermatophytes .
    Oteseconazole
  • HY-B0852

    Cytochrome P450 Fungal Apoptosis Infection
    Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
    Tebuconazole
  • HY-114763

    Cytochrome P450 Parasite Infection
    LP8 is a Pyridinyl-type CYP51 inhibitor and can be used for study of chagas disease and American trypanosomiasis .
    LP8
  • HY-122410S

    Isotope-Labeled Compounds Cytochrome P450 Others
    Dihydrolanosterol-d7 is deuterium labeled Dihydrolanosterol. Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor[1].
    Dihydrolanosterol-d7
  • HY-113907

    VNF

    Cytochrome P450 Parasite Infection
    SDZ-285604 (VNF) is a T. cruzi CYP51 inhibitor and can be used for study of Trypanosoma cruzi infection .
    SDZ-285604
  • HY-17643R

    Fungal Cytochrome P450 Infection
    Oteseconazole (Standard) is the analytical standard of Oteseconazole. This product is intended for research and analytical applications. Oteseconazole (VT-1161) is a potent and orally active anti-fungal agent. Oteseconazole potently binds to and inhibits Candida albicans cytochrome P45051 (CYP51) activity (Kd ≤39 nM), shows no obvious effect on human CYP51. Oteseconazole also can be used for the research of dermatophytes .
    Oteseconazole (Standard)
  • HY-B0852R

    Cytochrome P450 Fungal Apoptosis Infection
    Tebuconazole (Standard) is the analytical standard of Tebuconazole. This product is intended for research and analytical applications. Tebuconazole is an orally active agricultural azole fungicide which can also inhibit CYP51 with IC50s of 0.9 and 1.3 μM for Candida albicans CYP51 (CaCYP51) and truncated Homo sapiens CYP51 (Δ60HsCYP51), respectively. Tebuconazole induces lipid accumulation and oxidative stress in HepG2 Cells. Tebuconazole decreases MAC-T cells viability and proliferation, induces ER-stress-mediated apoptosis and increases oxidative stress levels in MAC-T cells .
    Tebuconazole (Standard)
  • HY-116568R

    Fungal Cytochrome P450 Infection
    Prothioconazole (Standard) is the analytical standard of Prothioconazole. This product is intended for research and analytical applications. Prothioconazole is a triazolinthione fungicide. Prothioconazole is a CYP51 inhibitor .
    Prothioconazole (Standard)
  • HY-151440

    Fungal Infection
    Antifungal agent 42 is an antifungal agent. Antifungal agent 42 has an inhibitory effect on lanosterol 14α-demethylase (CYP51) of C.alb.. Antifungal agent 42 inhibits biofilm formation .
    Antifungal agent 42
  • HY-153618

    Fungal Infection
    Antifungal agent 53 (A03) is a potent inhibitor of Candida albicans CYP51 with antifungal activity. Antifungal agent 53 prevents the formation of fungi biofilms. Antifungal agent 53 also exhibits good safety .
    Antifungal agent 53
  • HY-136063

    Fungal Cytochrome P450 Infection
    Mefentrifluconazole is a novel azole derivative and used as an agrochemical broad-spectrum antifungal agent. Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM) .
    Mefentrifluconazole
  • HY-113648

    Others Infection
    LP10 is a non-azole CYP51 inhibitor with activity against Trypanosoma cruzi infection. Treatment with LP10 blocks the 14α-demethylation step, leading to disruption of the parasite cell membrane and ultimately triggering the death of important clinically relevant amoeba stages .
    LP10
  • HY-147919

    Fungal Infection
    Antifungal agent 33 (compound 4e) is a potent antifungal agent. Antifungal agent 33 exhibits remarkable antifungal activity against C. albicans, with a MIC of 16 μg/mL. Antifungal agent 33 shows potent inhibitory activity against Lanosterol 14α-demethylase (CYP51), with an IC50 of 0.19 μg/mL .
    Antifungal agent 33
  • HY-123777

    Fungal Infection Inflammation/Immunology
    VT-1598 is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 shows anti-fungal activity against Candida auris . VT-1598 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    VT-1598
  • HY-123777A

    Cytochrome P450 Infection
    VT-1598 tosylate is an orally active and selective fungal inhibitor targeting CYP51. VT-1598 tosylate shows anti-fungal activity against C. auris . VT-1598 (tosylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    VT-1598 tosylate
  • HY-W422288

    (Rac)-Ketoconazol; (Rac)-R 41400

    Fungal Cytochrome P450 Infection
    (Rac)-Ketoconazole ((Rac)-R 41400) is an antifungal imidazole compound with oral activity. (Rac)-Ketoconazole interferes with ergosterol synthesis by inhibiting cytochrome P450-dependent 14α-sterol demethylase (CYP51), a key enzyme on the fungal cell membrane, leading to membrane dysfunction and ultimately inhibition of fungal growth and reproduction. (Rac)-Ketoconazole is indicated for studies of fungal infections .
    (Rac)-Ketoconazole
  • HY-146464

    Fungal Infection
    Antifungal agent 30 (compound A18) is a potent antifungal agent. Antifungal agent 30 shows excellent antifungal activity against Candida albicans (CPCC400616) and Aspergillus fumigatus, with MIC of 0.03 and 0.5 μg/mL, respectively. Antifungal agent 30 also shows excellent antifungal activity against fluconazole-resistant strains. The potent antifungal activity of Antifungal agent 30 mainly causes by hydrogen and coordination bond interaction with the CYP51 .
    Antifungal agent 30
  • HY-117766

    Fungal Cytochrome P450 Infection
    PC945, a potent, long-acting antifungal triazole, possesses activity against a broad range of both azole-susceptible and azole-resistant strains of Aspergillus fumigatus. PC945 is also a potent, tightly binding inhibitor of A. fumigatus sterol 14α-demethylase activity, CYP51A and CYP51B, with IC50s of 0.23 μM and 0.22 μM, respectively .
    PC945
  • HY-155709

    Fungal Infection
    Antifungal agent 67 (compound 9) is an imidazole antifungal agent that is effective against Candida. Antifungal agent 67 has a CC50 value of 33.6 μM on healthy neonatal rat cardiomyoblasts .
    Antifungal agent 67

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: